The Global Medical Foods for Inborn Errors of Metabolism Market is witnessing substantial growth due to the increasing awareness of metabolic disorders and advancements in the formulation of specialized medical foods. Inborn errors of metabolism, such as phenylketonuria (PKU), maple syrup urine disease (MSUD), and homocystinuria, require tailored nutritional therapies to manage the conditions effectively. The growing prevalence of these disorders, coupled with a rise in genetic testing and early diagnosis, is driving demand for specialized medical foods. Additionally, the shift towards personalized nutrition and the development of innovative products that cater to the nutritional needs of patients are key factors contributing to the market's expansion. Regulatory approvals, government initiatives, and support for rare disease treatments further support the market's growth trajectory. As a result, the market is expected to continue growing, with new players and product innovations entering the space.
The global medical foods for inborn errors of metabolism size was valued at USD 3.12 billion in 2024 and is projected to reach USD 9.14 billion by 2032, with a CAGR of 14.39 % during the forecast period of 2025 to 2032.
To know more, visit https://www.databridgemarketresearch.com/ko/reports/global-medical-foods-for-inborn-errors-of-metabolism-market
Below are the Top Medical Foods for Inborn Errors of Metabolism Companies with a Significant Market Share:
|
Rank |
Company |
Overview |
Product Portfolio |
Sales Geographical Coverage |
Developments |
|
1. |
Abbott |
Abbott is a global healthcare company renowned for its medical devices, diagnostics, nutrition, and branded generic pharmaceuticals. Abbott holds the largest market share in the global medical foods for inborn errors of metabolism market, largely due to its innovative solutions like Abbott's metabolic formulae for managing inborn errors of metabolism (IEM) such as phenylketonuria (PKU). The company offers a range of medical nutrition products specifically formulated to meet the dietary needs of individuals with IEM. Abbott’s strong R&D capabilities and commitment to improving patient care make it a leading player in this specialized market. |
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe |
In May 2023, Abbott, Real Madrid, and the Real Madrid Foundation announced that during Real Madrid's final LaLiga match weekend of the 2022–2023 season, the organizations made the "Beat Malnutrition" campaign. The new campaign strengthens Abbott's collaboration with Real Madrid and the Real Madrid Foundation to eliminate worldwide childhood malnutrition by empowering communities to support children in achieving their full potential via nutrition education and malnutrition screening. |
|
2. |
Nestlé Health Science (A Subsidiary of Nestlé) |
Nestlé Health Science, a subsidiary of Nestlé, is a global leader in nutritional products, focusing on medical nutrition, digestive health, and metabolic care. Nestlé has a strong presence in the medical foods for IEM market through its Phenyl-Free and Medilab brands, which offer specially formulated medical foods to manage disorders like PKU. Nestlé Health Science’s expertise in medical nutrition and its commitment to improving metabolic health have cemented its position as one of the top companies in this market. The company continues to innovate in this area, offering nutritional solutions that help individuals with IEM live healthier lives. |
|
North America, South America, Asia-Pacific, and Europe |
In February 2022, Nestlé Health Science announced that the company has acquired Orgain, a pioneer in plant-based nutrition. This results in creating major share opportunities for the organization. Orgain adds to Nestlé Health Science's current line-up of nutritional goods that promote healthier lifestyles. Moreover, this also leads to an increase in the nutritional expansion of the company's business. This has aided the company's business expansion. |
|
3. |
Ajinomoto Cambrooke, Inc. (A Subsidiary of Ajinomoto Co., Inc.) |
Ajinomoto Cambrooke, a subsidiary of Ajinomoto Co., Inc., is a global leader in the development and manufacturing of medical foods for individuals with inborn errors of metabolism. The company specializes in producing medical nutrition products for metabolic disorders, including PKU and other amino acid-based disorders. Cambrooke’s products, like PhenylAde and Beneprotein, are scientifically formulated to meet the unique nutritional needs of individuals with IEM. Ajinomoto Cambrooke focuses on delivering high-quality, patient-centered solutions to improve metabolic management and quality of life. |
|
North America, South America, Asia-Pacific, and Europe |
In November 2018, Cambrooke Therapeutics Inc. (Ajinomoto Cambrooke, Inc.) received the OU-D certification for its glytactin GMP metabolic formulas and ketogenic liquid formulas. This has helped in the treatment of people suffering from epilepsy. The certification ensured product quality and safety. This has helped in gaining trust and also increased the revenue generation of the company in the market. |
|
4. |
Mead Johnson & Company, LLC. (A Subsidiary of Reckitt Benckiser Group plc.) |
Mead Johnson, a subsidiary of Reckitt Benckiser Group, is a well-established player in the global nutrition market, particularly in infant and medical nutrition. In the medical foods for IEM market, Mead Johnson offers specialized nutritional products like PKU Start and PKU Diet, designed to manage PKU and other metabolic disorders. The company’s extensive experience in formulating scientifically backed nutrition products and its global reach make it a prominent player in this market, supporting individuals with metabolic disorders to manage their conditions through diet. |
|
North America, South America, Asia-Pacific, and Europe |
In June 2017, Mead Johnson & Company, LLC. stated that it has been completely merged with Reckitt Benckiser Group plc (RB). It was expected that the Mead Johnson brand and business continued to flourish more with Reckitt Benckiser plc group’s good innovation and marketing process. This has led to strong growth and geographical expansion of the market. |
|
5. |
Nutricia |
Nutricia, a subsidiary of Danone, is a leader in specialized medical nutrition, with a strong focus on metabolic diseases, including inborn errors of metabolism. Nutricia offers a range of products under the Metabolics brand, which are specifically designed for individuals with IEM such as PKU, including PKU Anamix and Infantile PKU Formula. Nutricia’s expertise in medical foods, its focus on research and development, and its commitment to personalized nutritional care have made it a trusted name in the field of metabolic health. The company continues to innovate and provide high-quality, accessible nutrition solutions for individuals with IEM worldwide.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe |
In March 2019, Nutricia opened a sustainable plant in the Netherlands. The Nutricia Cuijk plant was a large investment and has increased the production of specialized infant formula along with the increased revenue generation in the market. |
Conclusion
Global medical foods for inborn errors of metabolism market is poised for significant growth, driven by increasing awareness, early diagnosis, and advancements in specialized nutritional therapies. The rising prevalence of metabolic disorders and the shift toward personalized nutrition are major contributors to the market's expansion. Additionally, regulatory support and continued innovation in product formulations are expected to further propel the market. As more players enter the space and new treatments emerge, the market is likely to see continued demand for tailored medical foods that address the unique nutritional needs of patients with inborn errors of metabolism.
